Cat. No.
MABL-1439
Application
theraputic, WB, ELISA, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
TRA-8
From
Recombinant Antibody
Specificity
The antibody is specific to human DR5 and does not bind other TRAIL receptors, other members of the TNF-receptor superfamily, or the murine homolog of DR5.
Alternative Names
TRAILR2; TNFRSF10B; TRAIL receptor 2; tumor necrosis factor receptor superfamily member 10B
UniProt
O14763
Immunogen
The antibody was raised by immunizing BALB/c mice with a fusion protein containing the extracellular portion of human DR5 and the Fc portion of human IgG1.
Application Notes
The antibody has been characterised using Western blot and ELISA. It induces apoptosis in primary hepatocellular carcinoma cells and established liver cancer cell lines, but not normal human hepatocytes (Ichikawa et al., 2001). The antibody has been reported to function in flow cytometry to detect cell-surface expression of DR5 on Cos-7 cells transfected with full-length human DR5. This antibody has been demonstrated to have therapeutic benefits in the treatment of cancer in vivo and ex vivo (Buchsbaum et al., 2003; PMID: 14506165) (Straughn Jr et al., 2006; PMID: 16271751) (Estes et al., 2007; PMID: 17303227).
Antibody First Published
Ichikawa et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nat Med. 2001 Aug;7(8):954-60. PMID:11479629
Note on publication
Describes the generation of the antibody, its characterisation and its function in triggering tumor apoptosis.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
